Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc.

Similar documents
The Czech National Health Care Information System (NH-IS) and its strategy in building population-based reporting

Challenges for Colorectal Cancer Screening

Faecal testing in colorectal cancer screening: State of the Art. Prof Stephen P. Halloran

Implementing of Population-based FOBT Screening

Primary care at the forefront of colorectal cancer screening

Czech CRC screening program at the point of switch to the population based design

FIT Laboratory update

EVALUATION OF QUANTITATIVE DETECTION OF FECAL HUMAN HAEMOGLOBIN FOR COLORECTAL CANCER SCREENING

Journal of Clinical Laboratory Instruments and Reagents, Vol. 34, No. 3 (June, 2011) Supplement

Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients

What I ll discuss. Head to Head Comparisons of Different FITs. What makes a FIT good? What makes a good FIT? Good performance

Comparison of FIT performance in screening programs. Carlo Senore

A Proposal to Standardize Reporting Units for Fecal Immunochemical Tests for Hemoglobin

Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening

Original Article General Laboratory Medicine INTRODUCTION

Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial

Friday, 17 October 2014: 08:30 11:30 * * * * *

Programme September 2017 Prague, Czech Republic

The Dutch bowel cancer screening program Relevant lessions for Ontario

FIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT

EVALUATION OF QUANTITATIVE FAECAL IMMUNOCHEMICAL TESTS FOR HAEMOGLOBIN

Practical challenges in establishing and running the Czech national colorectal cancer screening programme

FECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test

Friday, 23 October 2015: 10:15 12:00 * * * * *

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne

NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.

Colorectal Cancer Prevention Hospital Universitário São Paulo University

Reflections on the EUnetHTA CRC screening full Core Model pilot 1

An Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018

Information Pack for GP s The implementation of the Faecal Immunochemical Test (FIT) across the South West

T. Rubeca 1, S. Rapi 2, M. Confortini 1, M. Brogioni 2, G. Grazzini 1, M. Zappa 1, D. Puliti 1, G. Castiglione 1, S. Ciatto 1

Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30

The choice of methods for Colorectal Cancer Screening; The Dutch experience

Risk scoring incorporating FIT in triage of symptomatic patients

Friday, 15 May 2015: 10:00 12:00 * * * * *

Achieving 80% by 2018: Working Together Can Get Us There. Zachary Gregg, MD Sentara Martha Jefferson April 18, 2016

Colorectal cancer screening in England

North West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist

Fecal immunochemical testing results and characteristics of colonic lesions

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests

Citation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy

FREQUENTLY ASKED QUESTIONS

Sarvenaz Moosavi, 1 Robert Enns, 1 Laura Gentile, 2 Lovedeep Gondara, 2 Colleen McGahan, 2 and Jennifer Telford Introduction

University of Dundee. Published in: Journal of Medical Screening DOI: / Publication date: 2016

A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test

Colorectal cancer screening

Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s

The York Faecal Calprotectin Care Pathway for use in primary care. James Turvill

LIPPINCOTT WILLIAMS AND WILKINS

FIT Overview. Objectives 6/23/2014

Bowel Cancer Screening Exploiting science brings better medicine

University of Dundee. Published in: Annals of Clinical Biochemistry DOI: / Publication date: 2017

WEO CRC SC Meeting. Vienna, Austria October 14, 2016

Adding family history of colorectal cancer to the FIT-based screening program in a Dutch screening population sample

Chicago th Meeting of the Expert Working Group (EWG) FIT for Screening MEETING REPORT

Microbiome as a marker for CRC screening

SE65. guidelines. Background! Methods!

Get tested for. Colorectal cancer. Doctors know how to prevent colon or rectal cancer- and you can, too. Take a look inside.

Foreword. FIT for Purpose

(Bowel) Cancer Screening an update. Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Jun; 156(2):

Immunochemical Faecal Occult Blood Test for Colorectal Cancer Screening: A Systematic Review

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?

Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * *

Colorectal Cancer Screening

Implementation of Faecal Immunochemical Testing as the screening test for Bowel Screening. Programme in Wales

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial

IJC International Journal of Cancer

Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences

CRC screening from the viewpoint of its clients and patients results of survey

Title: Immunochemical Fecal Occult Blood Tests. Date: June 15, 2007

Multitarget Stool DNA Testing for Colorectal-Cancer Screening. Axel Bauer, M.D. Konstantinos D. Rizas, M.D.

Are you ready for the Colorectal Cancer Screening Pilot Programme?

Cologuard Screening for Colorectal Cancer

Rapid-VIDITEST Calprotectin

TPMG experience in improving colorectal cancer screening rates

Updates in Colorectal Cancer Screening & Prevention

Early detection and screening for colorectal neoplasia

EU Guidelines for quality assurance in organization, implementation and monitoring of colorectal cancer screening programme. Jožica Maučec Zakotnik

References. Valorization

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests

Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M.

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)

American Indian and Alaska Native Colorectal Cancer Screening Data April 26, 2016

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

Evaluating new tests: Which characteristics are important? Graeme Young

ColonCancerCheck Program Report

Dr Alasdair Patrick Gastroenterologist

Combination of Sigmoidoscopy and a Fecal Immunochemical Test to Detect Proximal Colon Neoplasia

C olorectal cancer (CRC) is the second most common

FIT for symptomatic patients. Facilitator name

COLORECTAL CANCER SCREENING &THE FECAL IMMUNOCHEMICAL TEST (FIT) MATHEW ESTEY, PHD, FCACB CLINICAL CHEMIST

INTERACTION WITH SCREENEES AND PATIENT ORGANIZATIONS

Get FIT for the new year: a review of the role of faecal immunochemical test for haemoglobin in patients with symptoms of colorectal disease

Engaging Primary Care in bowel screening

Transcription:

Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc. European Digestive Cancer Days, Prague - 26. September 2017

QUANTITATIVE FIT FOR CRC SCREENING Quantitative FIT are replacing traditional guaiac FOBT in population screening programs for many reasons. Quantitative FIT achieves 90% sensitivity for CRC detection and is therefore at least 3 times more sensitive than guaiac test Quantitative FIT needs to be optimised for population screening with professional, epidemiological and economic aspects Quantitative FIT offer much more than just FOBT+/ +/FOBT- results, and FIT cut-off could significantly modify the screening programs Quantitative FIT are developed over 20 years, and over the past 20 years there are 5189 publications in MEDLINE (09/2017) 2

Can.J.Gastro.Hepatol. - 06/2016 Quantitative one FIT test (NS-Plus, Alfresa) ) with cut-off 10 μg/g 20 322 FIT positive subjects underwent colonoscopy. Cut-off 10 μg/g with all adenoma detection exceeds national recommendations 60 and endoscopic sources need to be considered. 50 40 30 20 10 CRC - cancer adenoma high-risk adenoma low-risk 3 0 10-15 15-20 20-40 40-100 > 100 μg/g Shahidi N. Gentile L. Gondaraet L. al.: Can.J.Gastro.Hepatol.. 2016 Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program.

FIT ANALYSIS, FAECALF Hb CONCENTRATION, CUT-OFF Probability HEALTHY SUBJECTS ADENOMA LOW-RISK ADENOMA HIGH-RISK COLORECTAL CANCER 4 0 10 20 30 40 50 60 70 80 90 100 110 120 140 160 cut-off FIT cut-off gfobt μg/g

FIT 50 ng/ml (10 μg/g) FIT positivity 8-11 % Adenoma detection approx. 50 % CRC detection - 6,7 Effort to increase Sensitivity and Higher financial efficiency FIT 100 ng/ml (20 μg/g) Adenoma detection approx. 30 % CRC detection - 4,7 High false positivity Decrease number of colonoscopies gfobt positivity 3-5 % CRC detection - 3,1 FIT 200 ng/ml (40 μg/g) 5

SETTING THE CUT-OFF VALUE FIT TEST - FIT OPTIMISATION Determine sensitivity - rate of detected neoplasma /CRC Determine specificity - the numbers of 'unnecessary' colonoscopies Decide required capacity of GE centers and screening costs Accuracy and reliability of Hb analysis in stool 6 Standardization of FIT analysis Transferability of FIT analysis results External quality control of FIT analysis

J Natl Cancer Inst - 04/2012 Faecal immunochemical tests for Hb are replacing traditional guaiac faecal occult blood tests in population screening programs for many reasons. Many available faecalf immunochemical test devices use a range of sampling methods, differ with sampling methods, buffer volume and characteristics, Hb stability and results are expressed by different way. The current lack of consistency in units for Hb concentration is particularly problematic because apparently similar Hb concentrations obtained with different devices can lead to very different clinical interpretations. Consistent adoption of an internationally accepted method for reporting r results would facilitate comparisons of outcomes from these tests. We propose a simple strategy for reporting faecal Hb concentration 7 Fraser CG, Allison JE, Halloran SP, Young GP, Expert Working Group on Fecal Immunochemical Tests for Hemoglobin,, Colorectal Cancer Screening Committee WEO.. J Natl Cancer Inst 2012;104:810 14. 14. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin.

WEO Expert Working Group (EWG) Colorectal Cancer Screening Committee (CRC SC) First WG-FIT Meeting Euromedlab Athens 14. June 2017 IFCC Scientific Division Working Group Fecal Immunochemical Testing (WG-FIT) 8 To harmonise and/or standardise analysis of haemoglobin in faecal samples by immunochemistry (FIT)

J Lab Med Qual Assur - 10/2016 External quality control in Korea - in 2015 EQA analysis was conducted 3x during the year - 1,250 participants Qualitative tests - 569 participants (71%) - 9 different methods Qualitative tests provide false-positive results The success of the qualitative samples for negative sample was only 11% Quantitative FIT test - 235 participants (29%) - 7 different analyzers Totally different results depending on the technique used - in ng/ml 9 Chang-Ho Jeon and A-Jin A Lee, J Lab Med Qual Assur 2016;38:120-128 128 Annual Report on the External Quality Assessment Scheme for Urinalysis and Faecal Occult Blood Testing in Korea (2015)

FIT REALIZED BY GENERAL PRACTITIONER IN CZECH - 2014 QUESTIONNAIRE FOR PRACTITIONERS n = 522 g-fobt 3% Laboratory FIT 7.5% POCT FIT 23.5% Qualitative FIT 66% - 13 different methods - rapid tests 10 Král N., Seifert B., Korcová M.: Variability tests for occult blood used by general practitioners in screening for colorectal cancer in the Czech Republic. Gastroent Hepatol 2015 69(3): 255 258 258

ng/ml 250 225 200 175 150 125 100 11 /ml J Lab Med Qual Assur - 10/2016 75 50 25 0 POSITIVE SAMPLE NEGATIVE SAMPLE EQA Korea 2015 235 participants (29%) 7 different analyzers Results in ng/ml Chang-Ho Jeon and A-Jin A Lee, J Lab Med Qual Assur 2016;38:120-128 128 Annual Report on the External Quality Assessment Scheme for Urinalysis and Faecal Occult Blood Testing in Korea (2015) cut-off Eiken Eiken Eiken Alfresa Alfresa Kyowa Kyowa Micro Diana Io NS-1000 NS-C C HM-Jack HM-Jack Arc

Hb QUANTITATIVE ANALYSIS - FIT in CZECH REPUBLIC 12 External quality assessment Hb determination in the stool started in January 2012, as a part of the national EQA EQA programme provided by SEKK member of EQALM accredited ISO/IEC IEC 17043:2010 90 users in the Czech Republic EQA in Czech Republic - 2 liquid samples, twice per year

FIT EXTERNAL QUALITY ASSESSMENT IN CZECH REPUBLIC April 2016 μg/g Data from cycle FOB 2016-01 Eiken OC-Sensor Sentinel FOBGold CV - 8.10 % CV - 8.85 % FOB Gold analysis sample A - 50 μg/g sample B - 140 μg/g OC-Sensor analysis sample A - 30 μg/g sample B - 80 μg/g 1,6x higher 13 Kocna P., Zima T., Budina M., Ichiyanagi T.: External Quality Assessment ((EQA) for Quantitative Fecal Blood in Stool (FIT). Biochimica Clinica,, 2013, 37, 423

Gastroenterology - 03/2017 Screening with cut-off 15 μg/g according to OC-Sensor - Eiken study Predicted positivity - 6.3 % Screening done with the test FOB Gold - Sentinel FIT test positivity - 12.2 % 14 Cut-off has been modified to 47 μg/g to effort positivity 6.3 % Toes-Zoutendijk E, van Leerdam ME, Dekker E et all. : Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and a Optimization by Altering Fecal Immunochemical Test Cut-Off Levels. Gastroenterology 2017;152:767 775 775

Epidemiology of colorectal cancer: comparison of Czech regions FIT positivity in individual districts could be significantly affected by the FIT method used DC: 7,0 UL: 7,0 LI: 6,1 TP: 5,5 MO: 6,4 CL: 9,5 JN: 9,7 CV: 5,2 LT: 7,1 SM: 6,9 TU: 9,8 SO: 4,6 KV: 5,9 LN: 8,5 ME: 7,8 MB: 6,6 JC: 6,8 NA: 7,8 CH: 7,7 KD: 6,5 RA: 8,6 PH: 8,9 NB: 6,0 HK: 8,0 AX: 9,2 RK: 8,0 PS: 6,8 JE: 4,9 TC: 9,2 BE: 8,6 PZ: 7,6 KO: 7,6 PA: 5,9 RO: 11,4 PM: 7,2 UO: 8,2 KH: 9,3 SU: 5,9 BR: 8,2 CR: 6,7 PB: 7,5 PJ: 6,3 BN: 11,6 DO: 13,3 OP: 6,5 HB: 6,0 SY: 6,9 OT: 5,9KA: 4,6 PI: 6,5 OL: 6,4 KT: 5,2 TA: 6,1 PE: 6,8 ZR: 8,8 NJ: 6,3 ST: 8,6 BK: 6,2 PV: 6,9 PR: 6,5 JI: 6,8 FM: 7,5 PT: 9,2 BO: 6,9 JH: 8,7 VS: 6,2 TR: 8,6 BM: 7,6 VY: 8,5 KM: 6,6 CB: 6,8 ZL: 5,1 CK: 4,0 ZN: 6,8 BV: 7,2 Test positivity <5,0 5,0 6,5 6,5 8,0 8,0 9,5 > 9,5 Total positivity (2016) : 7.2 % Range UH: 6,7 HO: 6,4 between districts : 4,0 13,3 % 15 Májek O., Suchánek Š. Quality-assured assured immunochemical testing proposal for a pilot project in the Czech Republic European Digestive Cancer Days, Prague - 26. September 2017

TAKE HOME MESSAGE Efforts to change qualitative FIT to quantitative FIT Efforts to change units from ng/ml to μg/g of stool Standardization of FIT methods according to IFCC committee Essential requirement for FIT external quality control Personalized approach to FIT analysis of Hb in faeces Screening programs modifications using FIT values 16